Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16294838 | 1.00 | MEN1 (0.33) | MEN1MAPTKMT2AATMSMN1; SMN2 | |
| SCHEMBL19792667 | 0.90 | MEN1 (0.30) | MEN1MAPTKMT2AATMALDH1A1 | |
| SCHEMBL28662047 | 0.84 | LMNA (0.42) | MEN1KMT2AALDH1A1TP53CYP3A4 | |
| SCHEMBL17242140 | 0.84 | ALDH1A1 (0.49) | MEN1MAPTKMT2AALDH1A1TP53 | |
| SCHEMBL2905444 | 0.84 | ALDH1A1 (0.49) | MEN1MAPTKMT2AALDH1A1TP53 | |
| SCHEMBL10290412 | 0.80 | LMNA (0.54) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL5936419 | 0.79 | ALDH1A1 (0.33) | SMN1; SMN2ALDH1A1TP53CYP3A4LMNA | |
| SCHEMBL13244904 | 0.78 | CYP1A2 (0.39) | — | |
| SCHEMBL25284961 | 0.76 | MEN1 (0.42) | MEN1MAPTKMT2AATMSMN1; SMN2 | |
| SCHEMBL19267841 | 0.76 | MEN1 (0.46) | MEN1MAPTKMT2AATMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170029395-A1 | SYNTHESIS OF DERIVATIVES OF DICARBAMATES FROM REDUCTION PRODUCTS OF 2-HYDROXYMETHYL-5-FURUFURAL (HMF) | ARCHER DANIELS MIDLAND COMPANY | 2017-02-02 | — | — | US | disclosed |
| US-20170029395-A1 | SYNTHESIS OF DERIVATIVES OF DICARBAMATES FROM REDUCTION PRODUCTS OF 2-HYDROXYMETHYL-5-FURUFURAL (HMF) | ARCHER DANIELS MIDLAND COMPANY | 2017-02-02 | — | — | US | disclosed |
| US-20170029395-A1 | SYNTHESIS OF DERIVATIVES OF DICARBAMATES FROM REDUCTION PRODUCTS OF 2-HYDROXYMETHYL-5-FURUFURAL (HMF) | ARCHER DANIELS MIDLAND COMPANY | 2017-02-02 | — | — | US | disclosed |
| US-9487537-B2 | Synthesis of isohexide dicarbamates and derivatives thereof | ARCHER DANIELS MIDLAND CO. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487537-B2 | Synthesis of isohexide dicarbamates and derivatives thereof | ARCHER DANIELS MIDLAND CO. (US) | 2016-11-08 | — | — | US | disclosed |
| EP-3008058-A1 | SYNTHESIS OF DICARBAMATES FROM REDUCTION PRODUCTS OF 2-HYDROXYMETHYL-5-FURUFURAL (HMF) AND DERIVATIVES THEREOF | Archer Daniels Midland Company (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20160031842-A1 | SYNTHESIS OF ISOHEXIDE DICARBAMATES AND DERIVATIVES THEREOF | ARCHER DANIELS MIDLAND CO (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031842-A1 | SYNTHESIS OF ISOHEXIDE DICARBAMATES AND DERIVATIVES THEREOF | ARCHER DANIELS MIDLAND CO (US) | 2016-02-04 | — | — | US | disclosed |
| WO-2014200636-A1 | SYNTHESIS OF DICARBAMATES FROM REDUCTION PRODUCTS OF 2-HYDROXYMETHYL-5-FURUFURAL (HMF) AND DERIVATIVES THEREOF | ARCHER DANIELS MIDLAND COMPANY (US) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031842-A1 | SYNTHESIS OF ISOHEXIDE DICARBAMATES AND DERIVATIVES THEREOF | DCK, MCCC2, PRKAA1 | MEN1 214/4885MAPT 2005/4885KMT2A 1758/4885 |
| US-20170029395-A1 | SYNTHESIS OF DERIVATIVES OF DICARBAMATES FROM REDUCTION PRODUCTS OF 2-HYDROXYMETHYL-5-FURUFURAL (HMF) | MGMT, TKFC, DMPK | MEN1 200/4885MAPT 1854/4885KMT2A 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.